史蒂维oside 通过抑制 gasdermin D 途径来防止急性损伤
Ruochen Qiao1,2, Hui Wang3, Dasheng Li4
1Institute of Translational Medicine the Affiliated Drum Tower Hospital of Nanjing University Medical School Nanjing Jiangsu China.
Smart medicine
|August 27, 2024
概括
史蒂维oside通过向气皮素D (GSDMD) 途径,显示出治疗急性损伤 (AKI) 的前景. 这种天然化合物在临床前模型中减少了损伤和炎症.
科学领域:
- 腎臟病學 (nephrology) 是一種醫學.
- 分子生物学分子生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- 急性损伤 (AKI) 是一个全球性健康问题,死亡率高.
- 气体皮质D (GSDMD) 在AKI中显著上调,表明其在病理学中的作用.
研究的目的:
- 识别和验证向GSDMD途径的小分子抑制剂,用于AKI治疗.
- 为了研究在AKI中石化的治疗潜力.
主要方法:
- 对小分子进行针对LPS/Nigericin刺激的巨细胞的药物查,以确定GSDMD激活剂.
- 使用过氧化对管状上皮细胞进行AKI的体外模拟.
- 在体内AKI模型诱导的cisplatin和缺血/再输在小鼠.
主要成果:
- 石酸被确定为一种具有低毒性的强效GSDMD激活剂.
- 石酸治疗显著缓解管皮细胞损伤和AKI组织学损伤在体外和体内.
- 在治疗后观察到降低了切割的GSDMD-N终端和炎症因素的水平.
结论:
- 石酸对AKI具有显著的治疗潜力.
- 调节GSDMD信号与stevioside为AKI治疗提供了一个有希望的治疗策略.
相关概念视频
Antihypertensive Drugs: Direct Renin Inhibitors
512
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
512
Antihypertensive Drugs: Potassium-Sparing Diuretics
477
Liddle syndrome is a genetically inherited form of hypertension characterized by the overactivity of epithelial sodium channels in the nephron, the functional unit of the kidney. This heightened activity leads to increased sodium reabsorption and excessive excretion of potassium. To counteract this, potassium-sparing diuretics such as amiloride are used. They function by blocking these sodium channels, thereby reducing the influx of sodium into the epithelial cells and minimizing the loss of...
477
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
405
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
405


